Clinical Features of Pulmonary Large Cell Neuroendocrine Carcinoma.
- Author:
Moo Suk PARK
1
;
Kil Dong KIM
;
Jae Ho CHUNG
;
Dong Hwan SHIN
;
Kyung Young CHUNG
;
Joo Hang KIM
;
Chang Yul LEE
;
Young Sam KIM
;
Hyung Joong KIM
;
Se Kyu KIM
;
Chul Min AHN
;
Sung Kyu KIM
;
Joon CHANG
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. chang@yumc. yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Lung neoplasm;
Large cell;
Carcinoma;
Neuroendocrine tumor
- MeSH:
Carcinoma, Neuroendocrine*;
Carcinoma, Small Cell;
Chromogranin A;
Cough;
Drug Therapy;
Female;
Humans;
Lung;
Lung Neoplasms;
Male;
Needles;
Neuroendocrine Tumors;
Prevalence;
Prognosis;
Retrospective Studies;
Smoke;
Synaptophysin;
Thyroid Gland;
Biomarkers, Tumor
- From:Cancer Research and Treatment
2003;35(3):245-253
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to investigate the clinical features of large cell neuroendocrine carcinomas (LCNEC). MATERIALS AND METHODS: We retrospectively reviewed the histopathology and clinical information of 37 patients with LCNEC, diagnosed between June 1992 and May 2002 at the Severance Hospital, and performed immunohistochemical (IHC) staining. RESULTS: The prevalence of LCNEC among primary lung cancers was 0.3%, 37 out of 13, 012 cases over a 10 year period. The mean age was 61+/-12 years old, with 34 (92%) males and 3 (8%) females. 30 patients smoked, with an average of 42 packs per year. A cough was the most frequent symptom. The tumor was located at the periphery of the lung in 24 cases (65%). Among the 30 cases that underwent surgery, 4 were diagnosed pathological stage IA, 11 IB, 1 IIB, 13 IIIA and 1 IIIB. The 7 clinically non-operable cases were IIIB in 3, and IV in 4. The positive rates of CD56, thyroid transcription factor-1 (TTF-1), chromogranin A, synaptophysin and 34betaE12 for tumor cells were 88.9, 55.6, 42.1, 31.6 and 21.1%, respectively, from the IHC staining. The median survival time and 5 year-survival rate were 24 months and 27%, respectively. The group that underwent surgery had a better prognosis than those that did not. CONCLUSION: The positive rates for the tumor markers varied, but those of the CD56 and TFT-1 were the highest. The possibility of LCNEC needs to be evaluated for the following situations: small cell carcinomas located at the periphery and not responding chemotherapy, small cell carcinomas diagnosed by percutaneous needle aspiration, poorly differentiated non-mall cell carcinomas, with uncertain histologic type, and unclassified neuroendocrine tumor, etc.
